ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $102.1429.

ANIP has been the topic of several research reports. JPMorgan Chase & Co. lifted their target price on ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Guggenheim raised their price target on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a report on Monday, November 10th. HC Wainwright upped their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Barclays initiated coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target for the company. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $78.66 on Tuesday. ANI Pharmaceuticals has a one year low of $52.74 and a one year high of $99.50. The company’s fifty day moving average price is $83.88 and its 200-day moving average price is $82.94. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. The company has a market capitalization of $1.77 billion, a PE ratio of 48.26 and a beta of 0.51.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. The company had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. During the same period last year, the company posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, equities analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, Director Patrick D. Walsh sold 8,643 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $86.88, for a total value of $750,903.84. Following the completion of the sale, the director owned 61,405 shares in the company, valued at approximately $5,334,866.40. The trade was a 12.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,622 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the transaction, the senior vice president owned 58,564 shares in the company, valued at approximately $4,825,673.60. This represents a 2.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 28,001 shares of company stock worth $2,446,934. 12.70% of the stock is currently owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership bought a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth $32,992,000. Balyasny Asset Management L.P. grew its stake in ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP bought a new position in ANI Pharmaceuticals in the third quarter worth about $21,454,000. Rubric Capital Management LP lifted its position in shares of ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after buying an additional 200,998 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.